Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 2,913 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Event Clear all

Conditions: Molluscum Contagiosum, Skin Disease
Interventions: cantharidin's vehicle, Cantharidin 0.7%; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 5 Years to 10 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Acute Coronary Syndrome
Interventions: Darapladib 160 mg, Placebo, Standard Therapy; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 13,026 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 290
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 252 more

Conditions: Posttraumatic Stress Disorder, Depressive Symptoms, Burn Out, Anxiety, Work Related Stress
Interventions: WET; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Critical Illness, Acute Kidney Injury
Interventions: 0.9% Saline, Physiologically-balanced isotonic crystalloid; Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 5,381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Obstructive Sleep Apnea, Heart Failure; With Decompensation
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 80 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: San Diego, California

Conditions: Cardiovascular Disease, Cerebrovascular Accident, Coronary Heart Disease
Interventions: Atorvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 8,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 181
States / cities: Alabaster, Alabama • Birmingham, Alabama • Hoover, Alabama + 129 more

Conditions: Asthma
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 6 Years and older
Enrollment: 151 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer
Interventions: Trastuzumab emtansine, Treatment of physician's choice; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 59
States / cities: Tucson, Arizona • Hot Springs, Arkansas • Hayward, California + 52 more

Conditions: Critical Illness, Acute Kidney Injury
Interventions: 0.9% Saline, Physiologically-balanced isotonic crystalloid; Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 10,421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: End-stage Renal Disease
Interventions: Family Consultation; Behavioral
Lead sponsor: Mark A. Lumley; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Major Depressive Disorder
Interventions: Rapastinel (225 mg/450 mg IV administration); Drug
Lead sponsor: Naurex, Inc, an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 10
States / cities: Birmingham, Alabama • San Diego, California • Chicago, Illinois + 7 more

Conditions: Bipolar I Disorder, Bipolar II Disorder
Interventions: ABBV-932, Placebo for ABBV-932; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 32
States / cities: Dothan, Alabama • Anaheim, California • Colton, California + 28 more

Conditions: Influenza, Hepatitis A, Typhoid, Healthy Adults
Interventions: Fluzone® quadrivalent, Fluzone High Dose, Fluad, Vaqta, Typhim Vi, Vivotif; Biological
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Stanford, California

Conditions: Atrial Fibrillation
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 1,504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 66
States / cities: Mobile, Alabama • Scottsdale, Arizona • East Palo Alto, California + 58 more

Conditions: Liver Disease
Interventions: Eovist Contrast, Non Eovist Contrast; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 21 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: NSCLC
Interventions: Poziotinib, Docetaxel; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Winter Haven, Florida

Conditions: Adenotonsillar Hypertrophy, Obstructive Sleep Apnea, Tonsillitis, Adenoiditis
Interventions: Normal Saline, Dexmedetomidine; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 3 Years to 16 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Major Depressive Disorder, Persistent Depressive Disorder, Posttraumatic Stress Disorder, Panic Disorder, Social Phobia, Specific Phobia, Generalized Anxiety Disorder, Obsessive Compulsive Disorder
Interventions: Transdiagnostic Behavior Therapy, Behavioral Activation Therapy; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Arthritis, Polymyalgia Rheumatica, Immune Checkpoint Inhibitors
Interventions: Not listed
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pulmonary Arterial Hypertension
Interventions: inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin, oral ERA, oral PDE5 inhibitors; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: Not listed
Enrollment: 1,333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 88
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more

Conditions: Prostate Cancer
Interventions: Ipilimumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 3
States / cities: Evanston, Illinois • New York, New York • Portland, Oregon

Conditions: Surgical Wound Infection, Cross Infection
Interventions: SafeHaven Automated Hand Hygiene Device; Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Meningococcal Disease
Interventions: MenACWY-CRM; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 11 Years to 21 Years
Enrollment: 55,397 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 3
States / cities: Riverside, California • San Diego, California • Valley Annex, 16994 E. Valley Blvd., Fontana, California

Conditions: Melanoma
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 17,517 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: East Hanover, New Jersey

Search by objective public record fields.

Efficacy of Cantharidin in Molluscum Contagiosum

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial

Written Exposure Therapy for Nurses

Isotonic Solutions and Major Adverse Renal Events Trial in the Medical Intensive Care Unit

Sleep Disordered Breathing in Acute Congestive Heart Failure

A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels

Severe Asthma Research Program (SARP)- San Francisco Clinical Site

A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy

Isotonic Solutions and Major Adverse Renal Events Trial in the Non-Medical Intensive Care Unit (SMART-SURG)

Family Meeting Study for End Stage Renal Disease

Open Label Extension for GLYX13-C-202, NCT01684163

Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder

Effects of Aging on Primary and Secondary Vaccine Responses

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Is Eovist Suitable for Arterial-Phase MR Imaging of Liver

A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations

The Effect of Dexmedetomidine on Airway Complications After Deep or Awake Extubation

Transdiagnostic Psychotherapy for Veterans With Mood and Anxiety Disorders

A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer

Reducing Intraoperative ESKAPE Transmission Through Use of a Personal Hand Hygiene System

Safety of MenACWY-CRM Vaccination in Adolescents

Retrospective Assessment of AE-Related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma